Investors / United States / Regeneron Ventures
Regeneron Ventures
Corporate VC · Greenwich, CT, United States · North America
Regeneron Ventures is a health care venture capital fund launched in April 2024. It operates independently from its single and exclusive limited partner, Regeneron Pharmaceuticals, Inc., and invests to help build and grow companies that improve health.
Invests inHealthcare & Biotech
In its own wordshealthcarebiotechnologymedical devicesenabling technologieslife sciences
Your fit with Regeneron Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsRegeneron Ventures lists 11 checked portfolio companies on its own site and is named in 12 funding rounds, 3 of them as lead. Its most frequent entry is Series B, 55% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 91% of its companies are based in United States. It invests most often alongside Deerfield, RA Capital and Axial.
Counts come from funding rounds that name Regeneron Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundRegeneron Ventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 46% |
| Series B | 55% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 5 | 1 |
| '26 | 7 | 2 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 27th | 11 companies |
| Recent activity | 94th | 9 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 52th | 0% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Deerfield | 3 |
| RA Capital | 3 |
| Axial | 2 |
| Canaan | 2 |
| Droia Ventures | 2 |
| EcoR1 Capital | 2 |
| Lightspeed Venture Partners | 2 |
| Longwood Fund | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers11100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Regeneron Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Regeneron Ventures| Date | Company | Stage |
|---|---|---|
| 30 Oct 2026 | Series A | |
| 11 Aug 2026 | Series A Led | |
| 8 Jun 2026 | Series B | |
| 28 Apr 2026 | Series A | |
| 13 Apr 2026 | Series B | |
| 5 Mar 2026 | Series B | |
| 1 Jan 2026 | Series A Led | |
| 18 Dec 2025 | Series B |
Round details for Regeneron Ventures
Amounts, full round histories and every co-investor in Regeneron Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
11 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Actio Biosciences is involved in clinical trials for therapies, including for KCNT1-Related Epilepsy. | Healthcare & Biotech | Jun 2025Series B | Funding round | |
| Atavistik Bio is a clinical-stage biotechnology company developing innovative therapies for patients with serious hematologic diseases. | Healthcare & Biotech | Dec 2025Series B · 2 rounds | Funding round | |
| City Therapeutics is a clinical-stage biotechnology company developing the next generation of RNAi therapeutics designed to silence the expression of disease-relevant proteins | Healthcare & Biotech | Jun 2026Series B | Funding round | |
| Apr 2026Series A | Funding round | |||
| Infinimmune develops human-derived antibody medicines | Healthcare & Biotech | Aug 2026Series A | Funding round | |
| Neomorph develops molecular glue degraders to target and destroy disease-causing proteins. | Healthcare & Biotech | Apr 2026Series B | Funding round | |
| Setara Biosciences develops small-molecule precision medicines that target the underlying causes of disease | Healthcare & Biotech | Oct 2026Series A | Funding round | |
| Strand is a clinical-stage biotechnology company with a pipeline of breakthrough mRNA therapeutics for cancers and autoimmune diseases. | Healthcare & Biotech | Aug 2025Series B | Funding round | |
| The company develops small-molecule drugs using synthetic biology | Healthcare & Biotech | Jan 2026Series A | Funding round | |
| Triana Biomedicines discovers and develops small molecules that induce proximity of proteins to inactivate drivers of disease and deliver transformative therapies to patients | Healthcare & Biotech | Dec 2025Series B | Funding round | |
| Zag Bio develops therapies that target the thymus to treat autoimmune diseases by restoring balance to the immune system. | Healthcare & Biotech | Oct 2025Series A | Funding round |
About this data
site last read 13 Nov 2026- Site
- regeneronventures.com
- Last read
- 13 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 18 Jun 2025
- Companies checked
- 11
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Regeneron Ventures' profile as data
Pull Regeneron Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/regeneronventures.com
# also
GET /v1/firms/regeneronventures.com/portfolio
GET /v1/firms/regeneronventures.com/coinvestors
GET /v1/firms/regeneronventures.com/news